Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,483 | 356 | 99.9% |
| Education | $6.99 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,127 | 64 | $0 (2024) |
| GlaxoSmithKline, LLC. | $487.22 | 31 | $0 (2024) |
| Novo Nordisk Inc | $442.69 | 35 | $0 (2022) |
| Amgen Inc. | $421.96 | 32 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $378.45 | 25 | $0 (2023) |
| Merck Sharp & Dohme LLC | $304.72 | 17 | $0 (2024) |
| PFIZER INC. | $282.23 | 23 | $0 (2023) |
| Lilly USA, LLC | $235.38 | 16 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $225.41 | 14 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $216.17 | 15 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $589.37 | 36 | ABBVIE INC. ($306.52) |
| 2023 | $786.06 | 46 | AbbVie Inc. ($267.89) |
| 2022 | $1,698 | 112 | ABBVIE INC. ($400.43) |
| 2021 | $672.62 | 44 | AbbVie Inc. ($152.59) |
| 2020 | $376.07 | 26 | GlaxoSmithKline, LLC. ($64.61) |
| 2019 | $443.76 | 28 | Novo Nordisk Inc ($65.41) |
| 2018 | $502.31 | 37 | PFIZER INC. ($147.68) |
| 2017 | $421.56 | 28 | SANOFI-AVENTIS U.S. LLC ($79.47) |
All Payment Transactions
357 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: VACCINE | ||||||
| 11/13/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/29/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $28.28 | General |
| Category: NEUROLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: NEUROSCIENCE | ||||||
| 09/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: VACCINE | ||||||
| 08/28/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $2.74 | General |
| Category: NEUROSCIENCE | ||||||
| 07/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.75 | General |
| Category: NEUROSCIENCE | ||||||
| 07/23/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: NEUROSCIENCE | ||||||
| 07/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $10.23 | General |
| Category: NEUROSCIENCE | ||||||
| 06/27/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: NEUROSCIENCE | ||||||
| 06/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/17/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: NEUROSCIENCE | ||||||
| 06/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Endocrinology | ||||||
| 06/05/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: Diabetes | ||||||
| 05/23/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: NEUROSCIENCE | ||||||
| 05/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Cardio-renal | ||||||
| 05/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: NEUROSCIENCE | ||||||
| 04/25/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Biological | ||||||
| 04/23/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 173 | 207 | $4,761 | $1,171 |
| 2022 | 1 | 209 | 247 | $5,370 | $1,521 |
| 2021 | 2 | 180 | 215 | $5,273 | $1,468 |
| 2020 | 11 | 668 | 884 | $69,058 | $23,931 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 173 | 207 | $4,761 | $1,171 | 24.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 209 | 247 | $5,370 | $1,521 | 28.3% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 167 | 199 | $4,085 | $1,235 | 30.2% |
| 93227 | Heart rhythm tracing, analysis, and interpretation of 48-hour ekg | Facility | 2021 | 13 | 16 | $1,188 | $233.28 | 19.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 182 | 246 | $32,131 | $10,789 | 33.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 86 | 103 | $9,217 | $3,118 | 33.8% |
| 99307 | Subsequent nursing facility visit, typically 10 minutes per day | Office | 2020 | 15 | 83 | $5,835 | $2,469 | 42.3% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 275 | 328 | $6,366 | $2,024 | 31.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $3,957 | $1,353 | 34.2% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Office | 2020 | 12 | 25 | $2,713 | $1,300 | 47.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 19 | 19 | $1,520 | $999.20 | 65.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 25 | 26 | $1,573 | $706.62 | 44.9% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 14 | 14 | $1,757 | $653.68 | 37.2% |
| G0180 | Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implem | Facility | 2020 | 14 | 14 | $1,464 | $445.19 | 30.4% |
| 93922 | Ultrasound study of arteries of both arms and legs | Facility | 2020 | 11 | 11 | $2,525 | $72.10 | 2.9% |
About Dr. Harold Ayers, MD
Dr. Harold Ayers, MD is a Internal Medicine healthcare provider based in Pt Pleasant, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780783670.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harold Ayers, MD has received a total of $5,490 in payments from pharmaceutical and medical device companies, with $589.37 received in 2024. These payments were reported across 357 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($5,483).
As a Medicare-enrolled provider, Ayers has provided services to 1,230 Medicare beneficiaries, totaling 1,553 services with total Medicare billing of $28,091. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Adolescent Medicine
- Location Pt Pleasant, WV
- Active Since 09/21/2006
- Last Updated 12/10/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1780783670
Products in Payments
- QULIPTA (Drug) $547.18
- UBRELVY (Drug) $427.22
- TRELEGY ELLIPTA (Drug) $368.52
- JARDIANCE (Drug) $263.39
- ENTRESTO (Drug) $225.41
- BELSOMRA (Drug) $194.04
- Ozempic (Drug) $184.16
- SOLIQUA 100/33 (Biological) $156.24
- ELIQUIS (Drug) $150.26
- Repatha (Biological) $137.31
- Aimovig (Biological) $128.87
- XARELTO (Drug) $109.44
- CHANTIX (Drug) $92.63
- TRULICITY (Drug) $89.27
- TOUJEO (Drug) $88.10
- Victoza (Drug) $86.37
- Rybelsus (Drug) $85.65
- Veozah (Drug) $83.66
- XIFAXAN (Drug) $82.33
- SHINGRIX (Biological) $80.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.